Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease

Biological Psychiatry

Volumn 77, Issue 8, 2015, Pages 693-703

  Perez, Sylvia E ^a   He, Bin ^a   Nadeem, Muhammad ^a   Wuu, Joanne ^b   Scheff, Stephen W ^c   Abrahamson, Eric E ^d,e   Ikonomovic, Milos D ^d,e   Mufson, Elliott J ^a  

^a RUSH UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Amyloid; Mild cognitive impairment; Neuropathology; Neurotrophic factors; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; PITTSBURGH COMPOUND B; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE; TRITIUM; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; AMYLOID BETA PROTEIN; ANILINE DERIVATIVE; CHOLINE ACETYLTRANSFERASE; THIAZOLE DERIVATIVE;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BIOCHEMISTRY; COGNITION; DENSITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; NEUROPIL THREAD; NEUROTROPISM; PRECUNEUS; PRIORITY JOURNAL; SURVIVAL; DRUG EFFECTS; IN VITRO STUDY; MENTAL HEALTH; METABOLISM; NONPARAMETRIC TEST; PARIETAL LOBE; PATHOLOGY; PHYSIOLOGY; PRODROMAL SYMPTOM; SIGNAL TRANSDUCTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; CHOLINE O-ACETYLTRANSFERASE; FEMALE; HUMANS; IN VITRO TECHNIQUES; MALE; MENTAL STATUS SCHEDULE; MILD COGNITIVE IMPAIRMENT; NERVE GROWTH FACTOR; NEUROPIL THREADS; PARIETAL LOBE; PRODROMAL SYMPTOMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; THIAZOLES; TRITIUM;

EID: 84929657659     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2013.12.016     Document Type: Article

References (72)

1. Wagner AD, Shannon BJ, Kahn I, Buckner RL (2005): Parietal lobe contributions to episodic memory retrieval. Trends Cogn Sci 9:445-453.
2. Buckner RL, Andrews-Hanna JR, Schacter DL (2008): The brain's default network: Anatomy, function, and relevance to disease. Ann N Y Acad Sci 1124:1-38.
3. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL (2001): A default mode of brain function. Proc Natl Acad Sci U S A 98:676-682.
4. Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, LaViolette PS, Vitolo OV, et al. (2010): Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med 12:27-43.
5. Andrews-Hanna JR, Snyder AZ, Vincent JL, Lustinq C, Head D, Raichle ME, et al. (2007): Disruption of large-scale brain systems in advanced aging. Neuron 56:924-935.
6. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L, et al. (2002): Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17:302-316.
7. Matsuda H (2007): The role of neuroimaging in mild cognitive impairment. Neuropathology 27:570-577.
8. Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P (2005): Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: An fMRI study. Hum Brain Mapp 26:231-239.
9. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. (2006): [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67:446-452.
10. Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, et al. (2010): Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry 676:584-587.
11. Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, et al. (2009): Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63:178-188.
12. Drzezga A, Becker JA, Van Dijk KR, Sreenivasan A, Talukdar T, Sullivan C, et al. (2011): Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain 134:1635-1646.
13. Yan H, Zhang Y, Chen H, Wang Y, Liu Y (2013): Altered effective connectivity of the default mode network in resting-state amnestic type mild cognitive impairment. J Int Neuropsychol Soc 19:400-409.
14. Frisoni GB, Testa C, Sabattoli F, Beltramello A, Soininen H, Laakso MP (2005): Structural correlates of early and late onset Alzheimer's disease: Voxel based morphometric study. J Neurol Neurosurg Psychiatry 76:112-114.
15. Ishii K, Kawachi T, Sasaki H, Kono AK, Fukuda T, Kojima Y, et al. (2005): Voxel-based morphometric comparison between early- and late-onset mild Alzheimer's disease and assessment of diagnostic performance of z score images. AJNR Am J Neuroradiol 26:333-340.
16. Karas G, Scheltens P, Rombouts S, van Schijndel R, Klein M, Jones B, et al. (2007): Precuneus atrophy in early-onset Alzheimer's disease: A morphometric structural MRI study. Neuroradiology 49:967-976.
17. Scheff SW, Price DA, Schmitt FA, Roberts KN, Ikonomovic MD, Mufson EJ (2013): Synapse stability in the precuneus early in the progression of Alzheimer's disease. J Alzheimers Dis 35:599-609.
18. Ikonomovic MD, Klunk WE, Abrahamson EE, Wuu J, Mathis CA, Scheff SW, et al. (2011): Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease. Neurology 77:39-47.
19. Bulbarelli A, Lonati E, Cazzaniga E, Re F, Sesana S, Barisani D, et al. (2009): TrkA pathway activation induced by amyloid-beta (Abeta). Mol Cell Neurosci 40:365-373.
20. Fombonne J, Rabizadeh S, Banwait S, Mehlen P, Bredesen DE (2009): Selective vulnerability in Alzheimer's disease: Amyloid precursor protein and p75(NTR) interaction. Ann Neurol 65:294-303.
21. Yaar M, Zhai S, Pilch PF, Doyle SM, Eisenhauer PB, Fine RE, et al. (1997): Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. J Clin Invest 100:2333-2340.
22. Mufson EJ, Binder L, Counts SE, DeKosky ST, de Toledo-Morrell L, Ginsberg SD, et al. (2012): Mild cognitive impairment: Pathology and mechanisms. Acta Neuropathol 123:13-30.
23. Peng S, Wuu J, Mufson EJ, Fahnestock M (2004): Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathol Exp Neurol 63:641-649.
24. Mufson EJ, He B, Nadeem M, Perez SE, Counts SE, Leurgans S, et al. (2012): Hippocampal proNGF signaling pathways and β-amyloid levels in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol 71:1018-1029.
25. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS (2005): Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 64:834-841.
26. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. (2006): Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66:1837-1844.
27. Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett DA, Kordower JH (1999): Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol 158:469-490.
28. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR (1999): Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 58:376-388.
29. Schmitt FA, Nelson PT, Abner E, Scheff S, Jicha GA, Smith C, et al. (2012): University of Kentucky Sanders-Brown healthy brain aging volunteers: Donor characteristics, procedures and neuropathology. Curr Alzheimer Res 9:724-733.
30. Perez SE, Getova DP, He B, Counts SE, Geula C, Desire L, et al. (2012): Rac1b increases with progressive tau pathology within cholinergic nucleus basalis neurons in Alzheimer's disease. Am J Pathol 180:526-540.
31. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR (2000): "Preclinical" AD revisited: Neuropathology of cognitively normal older adults. Neurology 55:370-376.
32. Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU, Mufson EJ (2004): Reduction of cortical TrkA but not p75(NTR) protein in earlystage Alzheimer's disease. Ann Neurol 56:520-531.
33. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. (2008): Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131:1630-1645.
34. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, et al. (2005): Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25:10598-10606.
35. Ikonomovic MD, Abrahamson EE, Isanski BA, Debnath ML, Mathis CA, Dekosky ST, et al. (2006): X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease. Methods Enzymol 412:123-144.
36. Lad SP, Neet KE, Mufson EJ (2005): Nerve growth factor: Structure, function and therapeutic implications for Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 2:315-334.
37. Mesulam MM, Mufson EJ, Levey AI, Wainer BH (1983): Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nucleus, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 214:170-197.
38. Fahnestock M, Michalski B, Xu B, Coughlin MD (2001): The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci 18:210-220.
39. Al-Shawi R, Hafner A, Chun S, Raza S, Crutcher K, Thrasivoulou C, et al. (2007): ProNGF, sortilin, and age-related neurodegeneration. Ann N Y Acad Sci 1119:208-215.
40. Lee R, Kermani P, Teng KK, Hempstead BL (2001): Regulation of cell survival by secreted proneurotrophins. Science 294:1945-1948.
41. Masoudi R, Ioannou MS, Coughlin MD, Pagadala P, Neet KE, Clewes O, et al. (2009): Biological activity of nerve growth factor precursor is dependent upon relative levels of its receptors. J Biol Chem 284:18424-18433.
42. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, et al. (2004): Sortilin is essential for proNGF-induced neuronal cell death. Nature 427:843-848.
43. Pedraza CE, Podlesniy P, Vidal N, Arévalo JC, Lee R, Hempstead B, et al. (2005): Pro-NGF isolated from the human brain affected by Alzheimer's disease induces neuronal apoptosis mediated by p75NTR. Am J Pathol 166:533-543.
44. Fahnestock M, Yu G, Michalski B, Mathew S, Colquhoun A, Ross GM, et al. (2004): The nerve growth factor precursor proNGF exhibits neurotrophic activity but is less active than mature nerve growth factor. J Neurochem 89:581-592.
45. Podlesniy P, Kichev A, Pedraza C, Saurat J, Encinas M, Perez B, et al. (2006): Pro-NGF from Alzheimer's disease and normal human brain displays distinctive abilities to induce processing and nuclear translocation of intracellular domain of p75NTR and apoptosis. Am J Pathol 169:119-131.
46. Al-Shawi R, Hafner A, Olsen J, Chun S, Raza S, Thrasivoulou C, et al. (2008): Neurotoxic and neurotrophic roles of proNGF and the receptor sortilin in the adult and ageing nervous system. Eur J Neurosci 27:2103-2114.
47. Bruno MA, Cuello AC (2006): Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc Natl Acad Sci U S A 103:6735-6740.
48. Bruno MA, Mufson EJ, Wuu J, Cuello AC (2009): Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J Neuropathol Exp Neurol 68:1309-1318.
49. Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, et al. (2006): Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51:29-42.
50. Bruno MA, Leon WC, Fragoso G, Mushynski WE, Almazan G, Cuello AC (2009): Amyloid beta-induced nerve growth factor dysmetabolism in Alzheimer disease. J Neuropathol Exp Neurol 68:857-869.
51. Ward SM, Himmelstein DS, Lancia JK, Binder LI (2012): Tau oligomers and tau toxicity in neurodegenerative disease. Biochem Soc Trans 40:667-671.
52. Knowles JK, Rajadas J, Nguyen TV, Yang T, LeMieux MC, Vander Griend L, et al. (2009): The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo. J Neurosci 29:10627-10637.
53. Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, et al. (2003): Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 23:10879-10883.
54. Vehmas AK, Kawas CH, Stewart WF, Troncoso JC (2003): Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging 24:321-331.
55. Götz J, Schild A, Hoerndli F, Pennanen L (2004): Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: Insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci 22:453-465.
56. Nagy Z, Esiri MM, Jobst KA, Morris JH, King EM, McDonald B, et al. (1995): Relative roles of plaques and tangles in the dementia of Alzheimer's disease: Correlations using three sets of neuropathological criteria. Dementia 6:21-31.
57. Skeldal S, Matusica D, Nykjaer A, Coulson EJ (2011): Proteolytic processing of the p75 neurotrophin receptor: A prerequisite for signalling? Neuronal life, growth and death signalling are crucially regulated by intra-membrane proteolysis and trafficking of p75(NTR). Bioassays 33:614-625.
58. Mufson EJ, Kroin JS, Sendera TJ, Sobreviela T (1999): Distribution and retrograde transport of trophic factors in the central nervous system: Functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol 574:451-484.
59. Lakshmanan J, Beattie GM, Hayek A, Burns C, Fisher DA (1989): Biological actions of 53 kDa nerve growth factor as studied by a blot and culture technique. Neurosci Lett 99:263-267.
60. Mufson EJ, Ginsberg SD, Ikonomovic MD, DeKosky ST (2003): Human cholinergic basal forebrain: Chemoanatomy and neurologic dysfunction. J Chem Neuroanat 26:233-242.
61. NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem 97:475-487.
62. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, et al. (2002): Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51:145-155.
63. Ikonomovic MD, Mufson EJ, Wuu J, Cochran EJ, Bennett DA, DeKosky ST (2003): Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimers Dis 5:39-48.
64. Niewiadomska G, Mietelska-Porowska A, Mazurkiewicz M (2011): The cholinergic system, nerve growth factor and the cytoskeleton. Behav Brain Res 221:515-526.
65. Bhakar AL, Howell JL, Paul CE, Salehi AH, Becker EB, Said F, et al. (2003): Apoptosis induced by p75NTR overexpression requires Jun kinase-dependent phosphorylation of Bad. J Neurosci 23: 11373-11381.
66. Goedert M, Hasegawa M, Jakes R, Lawler S, Cuenda A, Cohen P (1997): Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett 409:57-62.
67. Reynolds CH, Nebreda AR, Gibb GM, Utton MA, Anderton BH (1997): Reactivating kinase/p38 phosphorylates tau protein in vitro. J Neurochem 69:191-198.
68. Vana L, Kanaan NM, Ugwu IC, Wuu J, Mufson EJ, Binder LI (2011): Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. Am J Pathol 179:2533-2550.
69. Driscoll I, Troncoso JC, Rudow G, Sojkova J, Pletnikova O, Zhou Y, et al. (2012): Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol 124:823-831.
70. Braak H, Braak E (1991): Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239-259.
71. Nelson PT, Abner EL, Scheff SW, Schmitt FA, Kryscio RJ, Jicha GA, et al. (2009): Alzheimer's-type neuropathology in the precuneus is not increased relative to other areas of neocortex across a range of cognitive impairment. Neurosci Lett 450:336-339.
72. Arnold SE, Louneva N, Cao K, Wang LS, Han LY, Wolk DA, et al. (2013): Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer's disease. Neurobiol Aging 34:157-168.